4.00
+0.04(+1.01%)
Currency In USD
| Previous Close | 3.96 |
| Open | 3.98 |
| Day High | 4.05 |
| Day Low | 3.87 |
| 52-Week High | 41.22 |
| 52-Week Low | 3.84 |
| Volume | 54,662 |
| Average Volume | 95,543 |
| Market Cap | 10.08M |
| PE | -0.31 |
| EPS | -12.93 |
| Moving Average 50 Days | 5.1 |
| Moving Average 200 Days | 9.79 |
| Change | 0.04 |
If you invested $1000 in Imunon, Inc. (IMNN) 10 years ago, it would be worth $0.67 as of November 10, 2025 at a share price of $4. Whereas If you bought $1000 worth of Imunon, Inc. (IMNN) shares 5 years ago, it would be worth $35.56 as of November 10, 2025 at a share price of $4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
GlobeNewswire Inc.
Nov 07, 2025 1:05 PM GMT
Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Pha
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
GlobeNewswire Inc.
Nov 06, 2025 1:05 PM GMT
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. ET o
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
GlobeNewswire Inc.
Nov 04, 2025 1:05 PM GMT
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 study investigators,